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ABSTRACT
In hematopoietic cell transplantation (HCT), natural killer cell alloreactivity conferred by inhibitory ligands of
killer immunoglobulin-like receptors (iKIRLs) may result in beneficial or detrimental outcomes. More data
may contribute to resolution of this complex issue. We analyzed 378 primary allogeneic transplants with
T-replete grafts for acute lymphoblastic leukemia (n  101), acute myeloid leukemia and myelodysplastic
syndrome (n  149), and chronic myeloid leukemia (n  128). The cohort was divided into 3 groups: in group 1,
HLA class I matched at the antigen level (n  260); in group 2, HLA class I mismatched at the antigen level
(n  57); and in group 3, HLA class I and iKIRLs mismatched (n  61). One-year overall survival (OS) across
groups 1 (59%), 2 (49%), and 3 (30%) was significantly different (P .002). In contrast to group 2, group 3 had
statistically lower OS (P  .05) and event-free survival (P  .01). Relapse and relapse-free mortality appeared
to contribute to the low OS in group 3. The detrimental effect of natural killer alloreactivity was also evident
when HLA-matched transplants were analyzed for patients lacking iKIRLs. One-year OS in patients lacking
the HLA-Cw group 1 or 2 iKIRL was significantly lower than that in patients having the iKIRLs (55% vs 67%,
n  246, P  .01). Our observations indicate that, in T-replete unrelated HCT, iKIRL mismatches and the
absence of iKIRLs confer higher risk to patients after HCT.
© 2007 American Society for Blood and Marrow Transplantation
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Natural killer (NK) cells that develop in bone
arrow comprise 5%-20% of lymphocytes in periph-
ral blood. Circulating human NK cells can be divided
nto 2 subsets based on surface density of CD56.
D56dim cells are mature NK cells capable of per-
orming cytotoxicity functions. CD56bright cells are a
inor population of NK cells with immature proper-
ies, which act as important sources of cytokines and
hemokines. NK cells participate in early innate im-
une responses, play an important role in immune
urveillance, and link the innate immune system to the
daptive immune system [1-3]. In clinical hematopoi-
tic cell transplantation (HCT), NK cells are the ﬁrst -ymphocytes to reconstitute. NK cells are also in-
olved in control of hematopoiesis [4,5].
Expressing a wide array of activating and inhibi-
ory receptors, NK cells perform effector and regula-
ory functions depending on the dialogue of incoming
timulatory and inhibitory signals. Killer immuno-
lobulin-like receptors (KIRs) are expressed on hu-
an NK cells and subsets of T cells, transmitting
nhibitory or stimulatory signals. KIR gene cluster
chromosome 19q13.4) consists of14 functional and
pseudo gene loci [6,7]. KIR gene expression is sto-
hastically regulated by genetic and epigenetic factors at
ranscriptional and post-transcriptional levels [8]. Some
nhibitory KIRs speciﬁcally recognize HLA-A, -B, or
Cw subgroup epitopes as inhibitory KIR ligands
197
(
H
8
(
2
s
a
g
c
w
o
i
c
“
b
t
m
N
h
t
d
a
p
i
i
r
t
i
a
c
m
g
g
m
c
T
a
v
a
u
e
c
M
P
t
o
2
r
l
m
c
s
r
r
p
a
a
w
w
r
t
t
a
m
b
l
b
p
c
u
c
a
H
p
D
K
m
d
p
a
2
C
a
o
i
G
a
a
e
m
a
i
G
m
w
p
a
i
g
p
m
r
f
J. Y. Sun et al.198iKIRLs). Subgroups include the well-deﬁned
LA-Cw group 1 (C1) epitope (asparagine at codon
0, Cw1, 3, etc) for KIR 2DL2/3, the Cw group 2
C2) epitope (lysine at codon 80, Cw2, 4, etc) for
DL1, the Bw4 epitope for 3DL1, and the inconclu-
ive A3, 11 for 3DL2. Some iKIRLs may also bind the
ctivating homologue KIRs with lower afﬁnity. Li-
ands for other activating KIRs have not yet been
learly identiﬁed. The interaction of inhibitory KIRs
ith these HLA class I epitopes controls the activities
f NK cells [9,10].
HCT between HLA-mismatched individuals may
nduce NK cell alloreactivity if the iKIRLs are also in-
ompatible. This alloreactivity can be explained by the
missing self” theory [9,10]. NK alloreactivity may also
e observed in HLA-identical sibling transplants under
he hypothesis of “missing iKIRLs,” an extension of the
issing self theory [11]. In clinical HCT, alloreactive
K cells may have graft-versus-leukemia effects, en-
ancement of graft tolerance, and anti-infection func-
ions. Conversely, they may mediate graft-versus-host
isease (GVHD) and graft rejection. Beneﬁcial effects of
lloreactive NK cells were observed in HCT with com-
letely T-depleted grafts [12,13]. In HCT with unmod-
ﬁed or incompletely T-depleted grafts, studies report-
ng beneﬁcial effects [14,15] are outnumbered by those
eporting deleterious outcomes [16-25]. We posited that
he effect of iKIRLs in T-replete HCT should be stud-
ed by considering the effect(s) of HLA-mismatched
lloreactive T cells. Most (if not all) iKIRL mismatches
an only be found in HLA class I antigen level mis-
atched transplant pairs. If the study subjects are
rouped by iKIRL compatibility alone, the incompatible
roup will contain only the HLA class I antigen level
ismatched transplants, whereas the other group will
ontain HLA compatible and incompatible transplants.
hus inferior outcomes may be attributable to T cell
lloreactivity. This concern has been thoroughly re-
iewed recently [26]. To analyze the relation of iKIRLs
nd T-replete HCT outcomes, we evaluated 378 cases
sing stringent criteria designed to isolate the iKIRL
ffect from the incompatible HLA effect. Our analysis
onﬁrmed the deleterious role of NK cell alloreactivity.
ETHODS
atients, Donors, and HCT Protocols
The present retrospective study evaluated 378 pa-
ients who received primary allogeneic transplants at
ur institution between January 1996 and December
003. The study was approved by our institutional
eview board. Patients were diagnosed as having acute
ymphoblastic leukemia (ALL), acute myeloid leuke-
ia and myelodysplastic syndrome (AML/MDS), or
hronic myeloid leukemia (CML; Table 1). Disease
tatus at HCT was considered as a risk factor for gelapse. CML in ﬁrst chronic phase was deﬁned as low
isk; CML in second chronic phase or accelerated
hase, AML or ALL in remission and MDS refractory
nemia subtype were considered as intermediate risk;
nd any stage beyond those as high risk [27]. Donors
ere unrelated or HLA mismatched related. Patients
ho underwent transplantation with HLA-identical
elated donors were not included in this study because
he clinical outcomes of these transplants are better
han that of unrelated donor transplants even matched
t HLA-A, -B, -Cw, -DRB1, and -DQB1 (10/10
atched). Grafts were bone marrow or peripheral
lood stem cells (PBSCs) according to standard col-
ection protocol. CD34 cell dose of PBSCs varied
etween 5 and 30  106/kg. CD34 cell count was not
erformed for bone marrow grafts. Neither ex vivo T
ell depletion nor in vivo antithymocyte immunoglob-
lin administration was included in any HCT proto-
ol. Conditioning and GVHD prophylaxis regimens
re listed in Table 1.
LA and KIR Genotyping
HLA typing of patients and donors was performed
rospectively for donor selection before HCT by
NA-based methods in high resolution. Retrospective
IR genotyping was performed with a multiplex poly-
erase chain reaction sequence speciﬁc primer method
eveloped in our laboratory [28]. Brieﬂy, in this multi-
lex method only 4 polymerase chain reactions can type
ll 14 functional KIR genes and a deletion variant of
DS4 that does not express membrane-bound protein.
riteria of HLA and iKIRL Incompatibility
nd Patients Lacking iKIRLs
All HCT pairs were matched at the antigen level
f HLA-DRB1. According to HLA class I compat-
bility, the cohort was classiﬁed into 3 groups.
roup 1 included recipients and donors compatible
t the antigen level of HLA class I. Split antigens
nd antigens in a cross-reactive group were consid-
red as mismatch. Group 1 also included molecular
ismatched cases, eg, different alleles in the same
ntigen group, and DQB1 disparate cases. All cases
n group 1 had no possibility of iKIRL disparity.
roup 2 consisted of HCT pairs that were mis-
atched at the antigen level of HLA class I, but
ere iKIRL matched. Group 3 contained trans-
lants that were mismatched at HLA class I antigens
nd iKIRLs (Table 1). Further analysis of HLA
ncompatibility between groups 2 and 3 showed that
roup 2 consisted of 44 single class I and 13 multi-
le HLA (double class I and/or class I plus DQB1)
ismatches, and Group 3 consisted of 49 and 12,
espectively. There is no statistically signiﬁcant dif-
erence in the extent of HLA mismatching between
roups 2 and 3. Assignment of iKIRL incompatibil-
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Detrimental Effect of NK Alloreactivity in HCT 199ty in GVH or host-versus-graft vector basically
ollowed a previously proposed algorithm [13-15].
n our cohort, 246 transplants with 10/10 matched
onors were also analyzed under the model of pa-
ients lacking iKIRLs [11]. We also considered the
IR genotyping results of patients and donors in both
odels. For example, in a homozygous HLA-Bw6 pa-
ient who underwent transplantation with a heterozy-
ous HLA-B donor, the iKIRL mismatch was counted
nly if the donor genotype had KIR3DL1.
linical Study Endpoints
Overall survival (OS) was calculated for the inter-
al between the dates of HCT and the last follow-up
isit or death. Event-free survival (EFS) was deﬁned as
able 1. Characteristics and Some Outcomes of Study Groups (n  37
Group 1
(n  260)
ge (y) at HCT‡ 39 (1-66)
iagnosis, n (row %)
ALL (n  101) 66 (65)
AML/MDS (n  149) 100 (67)
CML (n  128) 94 (74)
tatus at HCT, n (row %)
Low risk 71 (79)
Intermediate risk 98 (64)
High risk 91 (67)
onditioning, n (row %)
Myeloablative 214 (69)
Nonmyeloablative 46 (71)
VHD prophylaxis, n (row %)
CsA/FK506  MTX  steroid 195 (69)
CsA/FK506  MMF 65 (67)
onor type, n (row %)
Related 0 (0)
Unrelated 260 (71)
raft type, n (row %)
Bone marrow 183 (70)
PBSC 77 (67)
stimated 1-y OS, % (95% CI)††
Total 59 (53-65)
ALL 50 (38-62)
AML/MDS 51 (41-61)
CML 73 (64-81)
stimated 5-y relapse, % (95% CI)††
Total 24 (18-31)
ALL 46 (28-65)
AML/MDS 23 (13-37)
CML 13 (7-23)
CT indicates hematopoietic cell transplantation; GVHD, graft-v
phenolate mofetil; MTX, methotrexate; PBSC, peripheral blo
lymphoblastic leukemia; AML/MDS, acute myeloid leukemia a
Brieﬂy, group 1, HLA class I compatible cases; group 2, class I inco
receptor ligand incompatible cases (see details in Methods secti
Signiﬁcance tests were determined across groups 1-3/between gro
Median (range).
Wilcoxon rank-sum test.
Pearson chi-square test.
*Not applicable (NA) due to deliberate exclusion of related donor
†Estimates and 95% CIs; Mantel-Haenszel (log-rank) tests.he interval between the dates of HCT in hematologic cemission and ﬁrst relapse or death from any nonre-
apse cause. Nonrelapse mortality was used as the
imulation of transplant-related mortality (TRM). Di-
gnoses of remission and leukemic relapse were based
n cytomorphology and ﬂow cytometry. The diagno-
is and grading of acute GVHD (aGVHD) followed
he consensus criteria [29].
tatistical Analyses
Data regarding patient characteristics, HCT pro-
ocols, complications after HCT, and other outcomes
ere retrieved from our hospital information database
nd veriﬁed by the division of information sciences.
ilcoxon rank-sum test was used to analyze the dif-
erence in age at HCT. Survival outcomes were cal-
Group 2
(n  57)
Group 3
(n  61)* P†
29 (1-68) 36 (1-62) .001/.10¶
.27/.18#
15 (15) 20 (20)
21 (14) 28 (19)
21 (16) 13 (10)
.15/.69#
10 (11) 9 (10)
28 (18) 27 (18)
19 (14) 25 (19)
.28/.11#
51 (16) 48 (15)
6 (9) 13 (20)
.83/.61#
41 (15) 44 (16)
16 (16) 17 (17)
NA**/.45#
5 (38) 8 (62)
52 (14) 53 (15)
.56/.35#
41 (15) 39 (15)
16 (14) 22 (19)
49 (36-62) 30 (20-43) .002/.05
47 (24-71) 15 (5-38) .06/.03
43 (24-64) 28 (14-47) .08/.29
57 (36-76) 61 (33-83) .24/.61
20 (9-36) 45 (25-67) .06/.03
27 (9-60) 39 (17-67) .52/.24
17 (4-50) 71 (23-95) .19/.08
15 (4-44) 24 (6-63) .80/.62
ost disease; CsA, cyclosporine; FK506, tacrolimus; MMF, myco-
cell; OS, overall survival; CI, conﬁdence interval; ALL, acute
lodysplastic syndrome; CML, chronic myeloid leukemia.
le cases; group 3, class I and inhibitory killer immunoglobulin-like
nd 3 only.
lantations from group 1.8)
ersus-h
od stem
nd mye
mpatib
on).
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J. Y. Sun et al.200r last contact. Kaplan-Meier survival estimates were
ested using the Mantel-Haenszel (log-rank) test. In
ddition, 95% conﬁdent intervals on Kaplan-Meier
stimates were calculated using a logit transformation
f Greenwood estimates of the variances. Cox propor-
ional hazard regression was employed in developing
ultivariate models for the representative variables
nd the analyzed outcomes. Median follow-up time of
urvivors was 47 months (range, 3-116 months).
ESULTS
roup 3 Had the Lowest OS and EFS
f the Three Groups
After comparing patients after HCT in group 3
mismatched at HLA class I antigens and iKIRLs)
ith those in group 2 (mismatched at HLA class I
nly) and those in group 1 (matched at HLA class I
ntigens), we found that group 3 had the lowest rates
f OS (Figure 1A) and EFS (Figure 1B; P  .002).
ne-year estimates of OS were 59% (95% conﬁdence
nterval, 53%-65%) for group 1, 49% (36%-62%) for
roup 2, and 30% (20%-43%) for group 3. The dif-
erences between groups 2 and 3 were also statistically
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A. OS, (n=378)
P=0.002, among Group 1, 2 and 3
P=0.05, between Group 2 and 3
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P=0.0005, among Group 1, 2 and 3
P=0.01, between Group 2 and 3
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igure 1. Survival difference across 3 groups sorted by model of
nhibitory killer immunoglobulin-like receptor ligand mismatch
Table 1). Kaplan-Meier estimates for probabilities of (A) overall
urvival (OS) and (B) event-free survival (EFS). Mantel-Haenszel
log-rank) test was performed across the 3 groups (overall) and
etween groups 2 and 3 only.igniﬁcant for OS (P  .05) and EFS (P  .01), rndicating that iKIRL mismatches played a deleterious
ole in the outcomes of T-replete HCT (groups 2 and
had a similarly HLA-mismatched background).
HCT-related factors listed in Table 1, except age
t HCT, distributed similarly across the 3 groups,
ndicating that they did not contribute to the different
utcomes of the 3 groups. Other factors, such as
ytomegalovirus serology, gender proﬁles of recipi-
nts and donors, CD34 cell dose in the PBSC grafts,
LA molecular level incompatibility, and patients’
thnicity, were also analyzed, and no signiﬁcant dif-
erences were found across the 3 groups (data not
hown). The age at HCT and other factors closely
elated to HCT outcomes were analyzed in a mul-
ivariable analysis model (Table 2). These results
onﬁrmed that the iKIRL mismatch was an inde-
endent determinant of survival and relapse. Diag-
osis, conditioning regimen, and status at HCT
ere the strongest factors determining clinical out-
omes in this cohort.
ncompatible iKIRLs Affected Relapse and TRM
To analyze determinants that might result in
ower survival rates in group 3, we calculated relapse
ate and TRM among the 3 groups (Figure 2). The
elapse rate was statistically higher (P  .03) in
roup 3 than that in group 2 (Figure 2A). The
KIRL mismatch was an independent risk factor
etermining the relapse rate in the multivariate
nalysis that adjusted the effects of conditioning
egimen, diagnosis, and status at HCT (Table 2).
roup 3 also had the highest TRM, although it did
ot reach statistical signiﬁcance when compared
ith group 2 (P  .08; Figure 2B). We analyzed
GVHD among the 3 groups. The incidences of
evere aGVHD (grade III-IV) were 28% in group 1
nd 38% in groups 2 and 3 (P  .06), but there was
o signiﬁcant difference in severe aGVHD between
roups 2 (36%) and 3 (40%). In group 3, there were
5 cases of iKIRL mismatch in the GVH direction,
2 in the host-versus-graft direction, and 4 in both
irections. This further stratiﬁcation was not sig-
iﬁcantly related to the relapse rate or to the inci-
ence of aGVHD, but this may be due to the small
umber of cases.
etrimental Effect of NK Alloreactivity Was
bserved in HLA-Compatible HCT Cases
In the 246 transplantations with 10/10 matched
onors, no signiﬁcantly different distribution ofHCT-
elated factors was found between patients who lacked
he iKIRL HLA-C1 or -C2 and those who had the
KIRLs in an analysis similar to that presented in
able 1 (data not shown). In contrast, the OS rate of
atients who lacked C1 or C2 was signiﬁcantly infe-
ior to that of patients who had the iKIRLs (P  .01;
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Detrimental Effect of NK Alloreactivity in HCT 201igure 3A). One-year estimates of OS were 55%
47%-63%, n 141) in patients lacking C1 or C2 and
7% (58%-76%, n  105) in patients having the
KIRL. EFS differences were similar. Multivariate
nalysis using the same model of Table 2 conﬁrmed
hat lack of iKIRLs in patients was an independent
actor determining OS and EFS.
able 2. Multivariate Cox Proportional Hazard Regression Analyses of
Covariates* Relapse P
odel <.0001
tudy groups
1 1
2 0.69 (0.30-1.56) .37 1
3 2.98 (1.17-7.59) .02 1
ge at HCT
Risk/10 y 1.23 (1.01-1.50) .04 1
iagnosis
AML/MDS 1
ALL 1.99 (1.03-3.88) .04 1
CML 1.05 (0.46-2.39) .91 0
tatus at HCT
Low risk 1
Mid risk 4.43 (1.35-14.6) .01 1
High risk 6.20 (2.04-18.9) .001 1
onditioning
Reduced 1
Ablative 2.56 (1.06-6.19) .04 1
CT indicates hematopoietic cell transplantation; OS, overall s
AML/MDS, acute myeloid leukemia and myelodysplastic syndr
Data presented as relative risk (95% conﬁdence interval).
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A. TRM, n=378
Years after HCT
P=0.005, among Group 1, 2 and 3
P=0.08, between Group 2 and 3
Gp1, n=260
Gp2, 
n=57
Gp3, n=61
B. Relapse Rate, N=378
P=0.06, among Group 1, 2 and 3
P=0.03, between Group 2 and 3
Gp3, n=61
Gp1, n=260
Gp2, n=57
ytilibaborP evitalu
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C
igure 2. Factors contributing to differences in overall survival
smong the 3 groups. TRM indicates transplant-related mortality.Patients lacking C1 or C2 had a very signiﬁcantly
igher TRM (P  .004; Figure 3B). The incidence of
evere aGVHD for all diseases was signiﬁcantly higher
P  .03) in patients lacking C1 or C2 than that in
hose with the iKIRL (Table 3), suggesting that
GVHD contributed to the higher TRM in patients
acking C1 or C2.
ffect of NK Alloreactivity Varied
n Different Leukemias
Diagnosis is 1 of the major factors determining
CT outcomes (Table 2). Three common leukemias
n our study distributed similarly across the 3 groups
Table 1; P  .27). This suggests that poorer out-
omes in group 3 are not associated with the distribu-
ion of different diseases. We further examined the
etrimental effect of NK alloreactivity on survival in
ifferent diseases. OS and relapse data separated by
iagnosis are presented in Table 1. In contrast to
hose in group 2, 1-year estimates of OS in group 3
ere 32% lower for patients with ALL, 15% lower
or those with AML/MDS, and 4% higher for those
ith CML. Five-year estimates of relapse in group
were higher than those in group 2 by 12%, 54%,
nd 9% for ALL, AML/MDS, and CML, respec-
ively (Table 1).
Table 3 lists representative OS and aGVHD data
or the model of patients lacking iKIRLs. The dele-
erious role of NK alloreactivity was similar across the
diseases. Although the differences of OS and
GVHD for each disease group were not statistically
igniﬁcant, data pooled together did attain statistical
butions from Major Clinical Factors Related to HCT Outcomes
S P EFS P
<.0001 <.0001
1
88-1.84) .21 1.16 (0.80-1.67) .44
90-2.17) .13 1.65 (1.07-2.54) .02
01-1.24) .03 1.14 (1.03-1.26) .01
1
86-1.74) .26 1.30 (0.92-1.83) .14
28-0.78) .003 0.57 (0.35-0.91) .02
1
57-1.97) .86 1.24 (0.69-2.24) .47
97-2.99) .06 2.00 (1.17-3.40) .01
1
23-2.83) .004 1.93 (1.28-2.90) .002
; EFS, event-free survival; ALL, acute lymphoblastic leukemia;
ML, chronic myeloid leukemia.Contri
O
1
.27 (0.
.40 (0.
.12 (1.
1
.22 (0.
.47 (0.
1
.06 (0.
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.86 (1.
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tringent Criteria for Comparison
f iKIRL Mismatch
The present study observed inferior OS and EFS
the major clinical endpoints) in a group of patients
fter HCT sorted by a model of iKIRL mismatch. We
xamined our data with stringent criteria. First, we
onsidered the presence of iKIRL and the corre-
ponding KIR gene. Most studies have predicted
KIRL mismatches solely based on HLA typing re-
ults, often referred to the “ligand-ligand” model [13-
1]. As pointed out by a recent review, this assumption
s true in about 90% of transplantations [26]. Due to
he independent segregation of KIR and HLA genes,
n HCT pair may be classiﬁed as an iKIRL mismatch,
ut in reality there is no mismatch because the recip-
ent or donor does not have the corresponding KIR
ene. In Caucasians, 5% lack KIR3DL1 and 8% lack
IR2DL1 based on our own data and on those of
eports from other groups [30-32]. Thus, analysis may
e more accurate in predicting contribution of NK
ell alloreactivity to the clinical outcome of HCT. In
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igure 3. Analysis of clinical outcomes in HLA-compatible cases
ith a model of patients lacking inhibitory killer immunoglobulin-
ike receptor ligands. Patients with homozygous HLA-Cw group 1
r 2 (C1 or C2) were classiﬁed into 1 group (lacking C1 or C2, n 
41), and patients with heterozygous HLA-Cw regardless of ho-
ozygous HLA-Bw6 into another group (others). P value was
btained with the Mantel-Haenszel (log-rank) test. OS indicates
verall survival; TRM, transplant-related mortality.ur present data, 4 cases in the iKIRL mismatch †odel would be misclassiﬁed into group 3 if the pres-
nce of KIR genes was not considered; and 9 cases in
he model of patients lacking iKIRL have the same
ituation. Although this is a small number, once it was
isclassiﬁed, the effect would be doubled. Leung et al
12] reported that measurement of KIR expression in
onor NK cells provided the best predictive value.
owever, this approach is not feasible for retrospec-
ive studies. Nevertheless, the model based on iKIRLs
lone remained predictive in their study [12].
Another stringent criterion is that the statistical
nalyses were performed not only in the large cohort
ut also among the 2 smaller groups having compa-
able HLA class I mismatches, but differing in iKIRL
ompatibility. The importance of this statistical anal-
sis has been addressed in a recent review [26]. We
ere able to minimize the effect of T cell alloreac-
ivity in our analysis. The inferior outcomes in
roup 3 compared with those in group 2 can not be
xplained by T cell alloreactivity. In Table 1, the
-group classiﬁcation seems the same as that in a
ecent publication [15]. Actually, HLA-class I allele
evel mismatches were deliberately excluded from
roup 2.
nferior Outcomes in Patients Lacking iKIRLs
fter HLA-matched HCT
Homozygous HLA-Bw6, -C1, or -C2 in patients
ay also result in NK cell alloreactivity in HLA-
atched HCT. Superior [11] and inferior [23] out-
omes were reported in HLA-identical sibling
ransplantations. In our analysis of 246 unrelated
able 3. Effect of Lacking Inhibitory Killer Immunoglobulin-like
eceptor Ligands/HLA-Cw in Patients (n  246) Undergoing
ransplantation with Unrelated HLA-compatible Donors for Different
iseases
C1 or C2
(n  141)*
Others
(n  105) P†
stimated 1-y OS, mean %
(95%CI)
Total 55 (47-63) 67 (58-76) .01
ALL (n  61) 46 (31-62) 57 (36-76) .08
AML/MDS (n  92) 48 (35-62) 57 (42-72) .30
CML (n  93) 68 (54-79) 81 (67-90) .26
GVHD (III-IV), mean %
(95%CI)
Total 34 (26-43) 20 (14-30) .03
ALL (n  61) 35 (21-53) 17 (5-41) .25
AML/MDS (n  92) 31 (19-46) 26 (14-41) .67
CML (n  93) 36 (23-51) 17 (8-32) .02
S indicates overall survival; CI, conﬁdence interval; ALL, acute
lymphoblastic leukemia; AML/MDS, acute myeloid leukemia
and myelodysplastic syndrome; CML, chronic myeloid leuke-
mia; aGVHD, acute graft-versus-host disease.
Patients with homozygous HLA-Cw group 1 or 2 (C1 or C2) were
classiﬁed into this group and the “others” included patients with
heterozygous C1 and C2 regardless of homozygous HLA-Bw6.P value was obtained with the Mantel-Haenszel (log-rank) test.
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Detrimental Effect of NK Alloreactivity in HCT 203ransplantations with 10/10 matched donors, infe-
ior clinical outcomes were further observed in pa-
ients lacking C1 or C2 compared with those having
he iKIRLs. T cell depletion may be responsible for
hese observed differences.
In stratiﬁcation of iKIRL speciﬁcity (HLA-Bw4,
C1, or -C2) or dosage (lacking either or both
w4Cw), a dose effect and a speciﬁcity effect were
bserved by Hsu et al [11]. In our study (Table 4), the
-year estimates of OS in groups lacking 2, 1, or 0
KIRLs were 53%, 61%, and 70%, respectively. A
imilar trend of OS was noted among groups lacking a
peciﬁc iKIRL at 1- and 5-year periods. Cook et al
23] reported that patients lacking C1, but not C2, had
orse OS after HCT. OS of 24 patients lacking C1
as also the lowest in our study (Table 4). Recently,
his model was applied to a small cohort of unrelated
onor HCTs for diversiﬁed diseases; lower OS and
FS rates were also demonstrated in patients lacking
1, but not in those lacking C2 [24]. The consensus
mong these studies [23,24] and our study indicates
hat lacking iKIRL C1 is the major factor leading to
nferior outcomes. However, the best beneﬁcial effect
as observed in patients lacking Bw4 compared with
ther single iKIRLs [11].
otential Mechanisms Responsible for the
iversified Outcomes of NK Alloreactivity
To explain the lack of beneﬁcial effect in iKIRL-
ismatched HCT with T-replete grafts, donor T cells
ere proposed to dominate NK alloreactivity [22,33].
he presence of donor T cells was reported to delay
he maturation of newly generated NK cells [34].
bundant NKG2A and low KIR expression on imma-
ure NK cells do not support the beneﬁcial role of
KIRL mismatch in HCT using intensive T- and
K-depleted grafts [35]. However, it remains difﬁcult
o explain the mechanism responsible for a detrimen-
al role of NK alloreactivity in T-replete HCT. A
imple explanation is that the additional NK cell allo-
eactivity brings the overall alloimmune response be-
ond an appropriate level. Inappropriate alloreactivity
able 4. Inﬂuence of Each Speciﬁc iKIRL in the Model of Patients Lac
1 y
(n  74) 70 (59-79)
(Bw4, C1, C2) (n  104) 61 (51-70)
(Bw4C1, Bw4C2) (n  68) 53 (41-64)
one (n  74) 70 (59-79)
w4 alone (n  31) 65 (47-79)
2 and Bw4C2 (n  117) 57 (48-66)
1 and Bw4C1 (n  24) 54 (35-73)
KIRLs indicates inhibitory killer immunoglobulin-like receptor lig
Kaplan-Meier test comparing groups.eads to inferior clinical outcomes, although the tar- cets of NK cells may differ from those of T cells.
iversiﬁed effects of alloreactive NK cells were ob-
erved in HCT with T-replete or partially T-depleted
rafts [11,16-24,33,35]. It seems that there is a thresh-
ld of residual T cells that determines the effect of
K alloreactivity. Far below the threshold, NK allo-
eactivity plays a beneﬁcial role; above the threshold,
n adverse role. If residual T cells fall in a gray zone of
he threshold, no effect is observed. The threshold of
esidual T cells in the HLA-identical sibling HCT
11] may be higher than that in unrelated donor HCT
ecause the T cell alloreactivity is obviously weaker in
he former.
The cytotoxicity of mature NK cells harbored in
he graft is mainly controlled by iKIRLs. HLA class I
olecules of recipients have been reported to have a
ubtle, modulating effect on relative KIR expression
requencies [36]. Some studies in murine models also
ave suggested that major histocompatibility complex
lass I molecules select and educate the expression of
K cell receptors [37,38]. Interestingly, a recent study
eported that NK cell competence for cytokine pro-
uction and cytolysis was dependent on host major
istocompatibility complex class I molecules in mouse
odels [39]. KIRs are also expressed on subsets of T
ells ( T cells, CD4 and CD8 memory T cells)
nd profoundly inﬂuence peripheral tolerance and an-
igen-speciﬁc responses [40,41].
KIRL Effects in Different Leukemias
Most studies have reported that the beneﬁcial role
f NK alloreactivity can be observed in HCT only for
yeloid leukemia [13,15] or even only for AML and
DS, but not for CML [11]. Childhood ALL may be
he exception [12]. The detrimental role of NK allo-
eactivity was observed in cohorts with diversiﬁed dis-
ases including ALL [16-19,22] or in myeloid disease
nly [23,25]. We therefore included ALL in this study
nd were able to demonstrate a deleterious effect in
LL, AML/MDS, and CML (Table 2).
Our present study has conﬁrmed the deleterious
ole of NK alloreactivity in T-replete HCT. This
IRLs (n  246)
Point Estimates of OS, % (95%CI)
3 y 5 y P*
60 (49-71) 52 (40-64) .03
49 (39-59) 39 (28-51)
39 (28-51) 39 (28-51)
60 (49-71) 52 (40-64) .12
44 (28-62) 44 (28-62)
45 (36-55) 41 (31-51)
45 (27-65) 23 (7-54)
S, overall survival; CI, conﬁdence interval.king iK
ands; Oonclusion is based on our stringent criteria designed
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J. Y. Sun et al.204o minimize the effect of alloreactive T cells. The data
rovide insights into the confusing role of NK cell
lloreactivity and emphasize the importance of KIR
nd iKIRL in HCT. Clinical outcomes of NK allo-
eactivity may depend on many factors. A better un-
erstanding would enhance the beneﬁcial effect and
inimize the adverse effect of NK cell alloreactivity in
CT. A separate analysis for the relation of KIR
enotype to HCT clinical outcomes is underway.
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